CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Amoy Diagnostics Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Amoy Diagnostics Co Ltd
No.39, Dingshan Road, Haicang District
Phone: +86 5926806830p:+86 5926806830 XIAMEN, FUJ  361027  China Ticker: 300685300685
Business Summary
Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board LimouZheng 71 1/29/2021 2/1/2008
Chief Financial Officer, Secretary of the Board YingChen 54 4/29/2021 4/1/2015
Deputy General Manager, Director LiRuan 46 8/14/2024 8/14/2024
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,119 (As of 12/31/2023)
Outstanding Shares: 398,540,309 (As of 9/30/2024)
Shareholders: 17,836
Stock Exchange: SHE
Fax Number: +86 5926806203


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024